Point72 Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
Other funds holding RVNC
AAM
MF
TCM
WIC
Point72 Asset Management's RVNC Position: Q3 2024 in Review
Point72 Asset Management sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2024, closing a stake of 17,100 shares — an estimated $43.9K sold.
Point72 Asset Management first reported a position in RVNC in Q2 2019 and held it in 12 quarters. The position peaked at $21M in Q3 2021. 201 funds tracked by Wall St. Rank hold RVNC as of Q3 2024.
- Point72 Asset Management reported no remaining Revance Therapeutics, Inc. position as of Q3 2024 after selling out during the quarter.
- Point72 Asset Management sold 17,100 Revance Therapeutics, Inc. shares in Q3 2024, an estimated $43.9K.
- Point72 Asset Management first reported a position in Revance Therapeutics, Inc. in Q2 2019 and held it in 12 quarters.
- Point72 Asset Management's Revance Therapeutics, Inc. position peaked at $21M in Q3 2021.
- 201 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2024.
Based on Point72 Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.